AngioDynamics stock is undervalued, with Med Tech growth in thrombus management and atherectomy. Learn more about the company.
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, ...
AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback